Results 21 to 30 of about 912,051 (307)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant

open access: yesFrontiers in Immunology, 2022
The newly emerged Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains more than 30 mutations on the spike protein, 15 of which are located within the receptor binding domain (RBD).
Jinkai Zang   +8 more
doaj   +1 more source

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

open access: yesRNA Biology, 2022
Messenger RNA (mRNA) vaccines have been studied for decades, but only recently, during the COVID-19 pandemic, has the technology garnered noteworthy attention.
Nusrat Zahan Rouf   +4 more
doaj   +1 more source

In Gratitude for mRNA Vaccines

open access: yesNew England Journal of Medicine, 2021
mRNA Vaccine Research and the Lasker–DeBakey Award Although the production time (11 months) of the messenger RNA vaccines against SARS-CoV-2 infection set a record, the preclinical research undergi...
openaire   +2 more sources

mRNA Vaccine Platform: mRNA Production and Delivery

open access: yesRussian Journal of Bioorganic Chemistry, 2023
Vaccination is the most efficient way to prevent infectious diseases. mRNA-based vaccines is a new approach to vaccine development, which have several very useful advantages over other types of vaccines. Since mRNA encodes only the target antigen there is no potential risk of infection as in the case with attenuated or inactivated pathogens.
Litvinova, V. R.   +3 more
openaire   +2 more sources

OVERVIEW ON MRNA VACCINES BEYOND COVID-19

open access: yesInternational Journal of Infectious Diseases, 2023
COVID-19 mRNA vaccines: COVID-19 pandemic has made an extraordinary impact on global vaccine technology platform developments. Never in human history have there at least 6 vaccine platforms including: inactivated, protein subunit, VLP and other 3 new ...
Kiat Ruxrungtham
doaj   +1 more source

Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus

open access: yes, 2021
Conjugation of carbohydrate antigens with a carrier protein is a clinically proven strategy to overcome the poor immunogenicity of bacterial polysaccharide.
조상래
core   +1 more source

The Delivery of mRNA Vaccines for Therapeutics

open access: yesLife, 2022
mRNA vaccines have been revolutionary in combating the COVID-19 pandemic in the past two years. They have also become a versatile tool for the prevention of infectious diseases and treatment of cancers. For effective vaccination, mRNA formulation, delivery method and composition of the mRNA carrier play an important role. mRNA vaccines can be delivered
Nitika, Jiao Wei, Ai-Min Hui
openaire   +3 more sources

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

open access: yesPlatelets, 2022
In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine.
Mathilde Chanut   +7 more
doaj   +1 more source

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques

open access: yesFrontiers in Immunology, 2022
Immunogenicity of HIV-1 mRNA vaccine regimens was analyzed in a non-human primate animal model. Rhesus macaques immunized with mRNA in lipid nanoparticle (mRNA/LNP) formulation expressing HIV-1 Gag and Gag conserved regions (CE) as immunogens developed ...
Antonio Valentin   +17 more
doaj   +1 more source

mRNA Innovates the Vaccine Field [PDF]

open access: yesVaccines, 2021
Development of new vaccine modalities is a critical need to address many of the shortcomings of traditional platforms such as the lack of sufficient efficacy against certain pathogens or cancer; difficulties with production; or, in some cases, safety issues [...]
openaire   +3 more sources

Home - About - Disclaimer - Privacy